HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $9.00

Lexeo Therapeutics (NASDAQ:LXEO) had its price objective cut by HC Wainwright from $15.00 to $9.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 90.68% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on LXEO. Chardan Capital lowered their target price on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. JPMorgan Chase & Co. decreased their price target on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, May 30th. Finally, Oppenheimer began coverage on shares of Lexeo Therapeutics in a report on Thursday, July 31st. They issued an “outperform” rating and a $20.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and an average target price of $15.33.

Lexeo Therapeutics Trading Down 1.5%

Shares of LXEO stock opened at $4.72 on Friday. The company’s fifty day simple moving average is $4.32 and its two-hundred day simple moving average is $3.69. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.42 and a quick ratio of 3.42. Lexeo Therapeutics has a 1 year low of $1.45 and a 1 year high of $12.76. The stock has a market capitalization of $156.70 million, a price-to-earnings ratio of -1.45 and a beta of 1.36.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. As a group, analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LXEO. Allostery Investments LP bought a new position in Lexeo Therapeutics in the fourth quarter valued at $33,000. CWM LLC increased its stake in Lexeo Therapeutics by 150.3% in the second quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after acquiring an additional 6,216 shares during the last quarter. Ethic Inc. bought a new position in Lexeo Therapeutics in the second quarter valued at $44,000. Cerity Partners LLC bought a new position in Lexeo Therapeutics in the second quarter valued at $50,000. Finally, Intech Investment Management LLC increased its stake in Lexeo Therapeutics by 20.7% in the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after acquiring an additional 2,342 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.